A randomized, placebo-controlled study of the central cannabinoid (CB1) receptor antagonist rimonabant as adjunctive therapy to improve cognition in schizophrenia
Phase of Trial: Phase III
Latest Information Update: 04 May 2013
At a glance
- Drugs Rimonabant (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Therapeutic Use
- 23 Jun 2012 Actual initiation date (Sep 2008) added as reported by European Clinical Trials Database record.
- 19 May 2012 Company added to the associations field as reported by European Clinical Trials Database record.
- 02 May 2012 New trial record